D.A. Davidson & CO. Decreases Stock Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM)

Posted by on Apr 29th, 2023

D.A. Davidson & CO. decreased its holdings in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM – Get Rating) by 7.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 9,930 shares of the company’s stock after selling 850 shares during the quarter. D.A. Davidson & CO.’s holdings in Axsome Therapeutics were worth $766,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of AXSM. Captrust Financial Advisors raised its stake in Axsome Therapeutics by 582.0% during the first quarter. Captrust Financial Advisors now owns 757 shares of the company’s stock valued at $31,000 after purchasing an additional 646 shares in the last quarter. Armstrong Advisory Group Inc. purchased a new stake in shares of Axsome Therapeutics in the fourth quarter valued at $33,000. Quent Capital LLC purchased a new stake in shares of Axsome Therapeutics in the third quarter valued at $54,000. Signaturefd LLC raised its stake in shares of Axsome Therapeutics by 627.0% in the fourth quarter. Signaturefd LLC now owns 727 shares of the company’s stock valued at $56,000 after acquiring an additional 627 shares during the period. Finally, Great West Life Assurance Co. Can purchased a new stake in shares of Axsome Therapeutics in the third quarter valued at $69,000. Hedge funds and other institutional investors own 59.71% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the stock. Morgan Stanley reduced their target price on shares of Axsome Therapeutics from $85.00 to $83.00 and set an “equal weight” rating on the stock in a research note on Wednesday, April 12th. Piper Sandler assumed coverage on shares of Axsome Therapeutics in a research note on Thursday, January 5th. They issued a “neutral” rating and a $75.00 target price on the stock. Guggenheim reduced their target price on shares of Axsome Therapeutics from $105.00 to $90.00 and set a “buy” rating on the stock in a research note on Tuesday, February 28th. StockNews.com started coverage on shares of Axsome Therapeutics in a research note on Thursday, March 16th. They issued a “sell” rating on the stock. Finally, Mizuho reaffirmed a “buy” rating and issued a $84.00 price target on shares of Axsome Therapeutics in a research note on Monday, March 13th. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and ten have issued a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $103.79.

Axsome Therapeutics Stock Up 0.5 %

Shares of Axsome Therapeutics stock opened at $71.53 on Friday. The company has a debt-to-equity ratio of 0.86, a current ratio of 2.54 and a quick ratio of 2.50. Axsome Therapeutics, Inc. has a 1 year low of $20.63 and a 1 year high of $82.00. The firm’s 50-day moving average is $64.64 and its two-hundred day moving average is $64.18. The stock has a market cap of $3.12 billion, a price-to-earnings ratio of -15.65 and a beta of 1.89.

Axsome Therapeutics (NASDAQ:AXSM – Get Rating) last released its quarterly earnings results on Monday, February 27th. The company reported ($1.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.18) by ($0.10). The firm had revenue of $24.37 million for the quarter, compared to analyst estimates of $21.51 million. As a group, research analysts expect that Axsome Therapeutics, Inc. will post -4.32 earnings per share for the current fiscal year.

Axsome Therapeutics Company Profile

(Get Rating)

Axsome Therapeutics, Inc is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview contain AXS-05, AXS-07, AXS-12, and AXS-14.

Read More

Want to see what other hedge funds are holding AXSM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Axsome Therapeutics, Inc. (NASDAQ:AXSM – Get Rating).

Institutional Ownership by Quarter for Axsome Therapeutics (NASDAQ:AXSM)

Receive News & Ratings for Axsome Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.